生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 04-27 16:00:00

5,840.752

-54.051

-0.92%

最高5,894.579	最低5,787.601	成交量1.55亿
今开5,894.579	昨收5,894.803	日振幅1.81%
总市值0.00	流通市值0.00	总股本0.00
成交额47.98亿	换手率--	流通股本0.00
市净率6.407641	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5840.7524,"timestamp":1777277308461,"preClose":5894.803,"halted":0,"volume":155013583,"delay":0,"changeRate":-0.009169,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-54.050781,"latestTime":"04-27 16:00:00","open":5894.5786,"high":5894.5786,"low":5787.6006,"amount":4797754266,"amplitude":0.018148,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"pbRate":6.407641,"peRate":-333.706545,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2630031601","title":"【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031601","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630031601?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:03","pubTimestamp":1777309406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 迈威生物-Ｂ 刊发全球发售配发结果公告，最终发售价厘定为每股27.64港元，股份将于2026年4月28日于港交所主板挂牌上市，每手买卖单位为200股。本次全球发售合共4713.02万股H股，其中香港公开发售4,713,200股，占全球发售10%；国际发售42,417,000股，占比90%。香港公开发售获大幅超额认购，有效申请126,378份，认购倍数约481.71倍，一手中签率为1.00%。国际发售获适度超额认购，认购倍数约3.46倍，承配人共82名。本次IPO未授出超额配售选择权。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","SPCX","IPOS","02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630318900","title":"君圣泰医药-B(02511.HK)授出最高1500万港元贷款","url":"https://stock-news.laohu8.com/highlight/detail?id=2630318900","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630318900?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:47","pubTimestamp":1777301223,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨君圣泰医药-B(02511.HK)公告，于2026年4月27日，公司与借款人刘利平订立贷款协议，据此，公司同意向借款人提供最高融资额达1500万港元的贷款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260427/32180948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630539011","title":"君实生物(01877)建议采纳2026年A股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630539011","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630539011?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:27","pubTimestamp":1777300020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，于2026年4月27日，董事会决议批准采纳公司2026年A股员工持股计划。2026年A股员工持股计划须经公司股东会审议批准后方能生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","399300","01877","688180","159982","BK1583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630970093","title":"加科思-B(01167)4月27日斥资47.28万港元回购6.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630970093","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630970093?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:08","pubTimestamp":1777298933,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年4月27日，该公司斥资47.28万港元回购6.6万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397093","title":"荣昌生物（688331）披露将参加2025年度制药行业集体业绩说明会，4月27日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397093","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397093?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:04","pubTimestamp":1777298696,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，荣昌生物报收于135.05元，较前一交易日上涨1.52%，最新总市值为762.33亿元。近日，荣昌生物发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00参加由上海证券交易所组织举办的上述集体业绩说明会，通过上证路演中心网络文字互动方式与投资者交流。公司将就2025年度经营成果、财务状况等投资者关注的问题进行回应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700045397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2148510915.USD","BK1574","LU2328871848.SGD","LU2488822045.USD","LU1064130708.USD","688331","01477","LU1969619763.USD","09995","BK1191","BK1161","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397311","title":"乐普生物-B(02157)拟委任范馨予为监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397311","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397311?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:47","pubTimestamp":1777297629,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B(02157)发布公告，董事会建议委任范馨予女士(范女士)为监事。倘获股东于股东周年大会上批准，彼之任期将自相关决议案于股东周年大会上获通过之日起至第二届董事会任期届满之日止，惟于彼的任期届满后可膺选连任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630394291","title":"上交所：将迈威生物-B(02493)调入沪港通下的港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2630394291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630394291?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:09","pubTimestamp":1777295366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日，上海证券交易所发布关于沪港通下港股通标的调整的通知。因上海证券交易所上市公司迈威生物(688062.SH)在香港联合交易所有限公司上市H股迈威生物-B(02493)，其H股不适用价格稳定期机制，且相应A股上市满10个交易日，根据《上海证券交易所沪港通业务实施办法》的有关规定，沪港通下港股通(以下简称港股通)标的名单发生调整，调入迈威生物-B(02493)，并自下一港股通交易日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02493","BK1161","688062","BK0239","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630239930","title":"翰思艾泰-B(03378)4月27日斥资105.83万港元回购3.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630239930","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630239930?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:16","pubTimestamp":1777292175,"startTime":"0","endTime":"0","summary":"翰思艾泰-B(03378)发布公告，于2026年4月27日该公司斥资105.83万港元回购3.8万股，回购价格为每股26.50-28.58港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_50.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_50.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1535","03378","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0071","BK0239","BK1574","BK0183","BK0209","BK0191","BK0175","002550","BK0028","300723","688117","BK0196","BK0216","BK0187","06978","600216","000963","LU1969619763.USD","000950","BK1161","688621","LU2328871848.SGD","301281","BK0250","BK0188","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393819","title":"科济药业-B(02171)：CT0596及CT1190B的研究结果摘要已被2026年EHA年会接受以壁报展示呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393819?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:05","pubTimestamp":1777287942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 发布公告，CT0596用于治疗复发╱难治性多发性骨髓瘤╱浆细胞白血病的IIT的研究结果摘要，及CT1190B用于治疗复发╱难治性B细胞非霍奇金淋巴瘤的IIT的研究结果摘要，已被2026年欧洲血液学协会年会接受进行壁报展示。摘要和进一步信息将于欧洲中部夏令时间2026年5月12日15:30后公布。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。本公司计划于2026年启动针对R/R MM和原发性浆细胞淋巴瘤的Ib期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","BK1574","BK1161","BK1587","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393872","title":"百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393872","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393872?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，2026 年 4 月 24 日，公司全资子公司百济神州广州与华辉安健签订了一份《合作协议》。此外，华辉安健同意在相关里程碑达成后，向百济神州广州支付其被百济神州广州授予相关知识产权许可的对价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","LU1251922891.USD","BK4526","688235","LU1969619763.USD","BK4588","BK4139","LU1303224171.USD","159992","LU0307460666.USD","06978","LU1770034418.SGD","06160","BK1574","BK1161","BK1583","BK4585","LU1719994722.HKD","BK0239","LU2328871848.SGD","LU0588546209.SGD","BK1588","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630398855","title":"亿腾嘉和(06998)4月27日斥资346.64万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630398855","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630398855?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:49","pubTimestamp":1777286982,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，该公司于2026年4月27日斥资346.64万港元回购100万股股份，每股回购价格为3.4-3.5港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06998","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630236060","title":"诺诚健华（688428）披露2026年股东周年大会通知，4月27日股价下跌1.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630236060","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630236060?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:36","pubTimestamp":1777286164,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，诺诚健华报收于27.91元，较前一交易日下跌1.97%，最新总市值为492.51亿元。该股当日开盘28.0元，最高28.3元，最低27.17元，成交额达3.52亿元，换手率为4.75%。近日，诺诚健华医药有限公司发布《关于召开2026年股东周年大会的通知》。公告显示，公司将于2026年6月16日召开2026年股东周年大会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK1574","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630436420","title":"昊海生物科技(06826)4月27日耗资约597.09万港元回购27.71万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630436420","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630436420?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:52","pubTimestamp":1777283548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)公布，2026年4月27日耗资约597.09万港元回购27.71万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","06826","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364650","title":"君实生物：2025年净亏损8.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364650","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630364650?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:36","pubTimestamp":1777282560,"startTime":"0","endTime":"0","summary":"南财智讯4月27日电，君实生物（01877.HK）公告，截至2025年12月31日止年度，公司总收入为24.98亿元人民币，同比增长28.23%；本公司拥有人应占年内亏损为8.48亿元人民币；每股基本亏损为0.84元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720272868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK0239","BK1515","BK1161","688180","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336631","title":"4月27日海创药业跌12.16%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630336631?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:29","pubTimestamp":1777278550,"startTime":"0","endTime":"0","summary":"证券之星消息，4月27日海创药业跌12.16%，收盘报41.03元，换手率3.15%，成交量3.12万手，成交额1.32亿元。重仓海创药业的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为16.53亿元，最新净值1.6872，较上一交易日下跌0.5%，近一年上涨24.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700029243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688302","BK1161","BK0239","09939","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630635700","title":"港股异动 | 维立志博-B(09887)午后涨超4% 核心产品LBL-024上市在即 展现重磅单品潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2630635700","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630635700?lang=zh_cn&edition=full","pubTime":"2026-04-27 14:52","pubTimestamp":1777272738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B午后涨超4%，截至发稿，涨2.28%，报85.3港元，成交额3735.49万港元。消息面上，维立志博近日宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性胃或胃食管结合部腺癌的Ⅱ期临床研究顺利完成首例患者入组。兴业证券则表示，LBL-024 上市在即展现重磅单品潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","BK4588","BK1161","HK0000500386.USD","09887","IPOS","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630637359","title":"港股开拓药业-B盘中涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630637359","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630637359?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:23","pubTimestamp":1777260219,"startTime":"0","endTime":"0","summary":"4月27日，开拓药业-B(09939.HK)盘中涨超8%，截至发稿涨8.86%，报2.95港元，成交额915.05万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273719895312.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273719895312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1515","BK4588","VXUS","BK4585","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630935581","title":"港股异动 | 和誉-B(02256)盘中涨超6% 于2026年AACR年会展示包含pan-KRAS等六项研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2630935581","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630935581?lang=zh_cn&edition=full","pubTime":"2026-04-27 10:27","pubTimestamp":1777256822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B盘中涨超6%，截至发稿，涨6.62%，报14.5港元，成交额1348.34万港元。消息面上，和誉-B发布公告，公司在4月17日至22日于美国圣地亚哥举行的美国癌症研究协会2026年年会上，以壁报形式展示了六项最新临床前研究及转化医学研究成果。研究结果表明，ABSK211可通过多机制协同显著增强抗肿瘤效果，为后续联合多种治疗策略进入临床开发提供了支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","BK4585","LU2488822045.USD","LU2476274720.SGD","VXUS","LU2778985437.USD","BK4588","BK1161","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2476274308.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630353293","title":"亚盛医药Bcl-2抑制剂利生妥®获 2026 版 CSCO系列指南多项重磅推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353293","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630353293?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:49","pubTimestamp":1777254540,"startTime":"0","endTime":"0","summary":"利沙托克拉是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。作为中国首个获批上市的国产原创Bcl-2抑制剂，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展现了该产品在多个血液肿瘤领域的卓越临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1221951129.SGD","LU0823417653.USD","BK4020","LU0942090050.USD","LU1571399168.USD","LU2237443465.HKD","BK4560","BK1161","IE000M9KFDE8.USD","BK4585","LU1032955483.USD","CSCL","BK4579","LU1066053197.SGD","CSCS","LU2247934214.USD","SG9999001424.SGD","LU1267930813.SGD","SG9999015945.SGD","LU1066051498.USD","LU1674673691.USD","BK4588","SG9999015986.USD","LU2286300806.USD","LU0868494708.USD","LU2237443622.USD","LU0234570918.USD","BK1574","LU1883839398.USD","LU1066051811.HKD","IE00B42XCP33.USD","AAPG","LU1059921491.USD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU0889566641.SGD","LU2102340556.USD","CSCO","LU0348723411.USD","BK4533","SG9999002224.SGD","LU0203345920.USD","LU2237443895.HKD","LU0203347892.USD","LU0234572021.USD","LU1162221912.USD","LU1244550577.SGD","LU1778281490.HKD","06855","IE00BVYPNV92.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}